CA
REGN icon

Callahan Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Callahan Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Sell
919
-5
-0.5% -$3.4K 0.04% 133
2026
Q1 		$714K Hold
924
– – 0.06% 126
2025
Q4 		$713K Sell
924
-7
-0.8% -$4.75K 0.06% 128
2025
Q3 		$524K Sell
931
-4
-0.4% -$2.26K 0.04% 123
2025
Q2 		$491K Hold
935
– – 0.04% 125
2025
Q1 		$593K Buy
935
+69
+8% +$47.5K 0.06% 124
2024
Q4 		$617K Buy
+866
New +$727K 0.06% 124

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Callahan Advisors's REGN Position: Q2 2026 in Review

Callahan Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 0.54% in Q2 2026, selling an estimated $3.4K and leaving 919 shares worth $573K. The position accounts for 0.04% of the portfolio, ranked #133.

Callahan Advisors first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $714K in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Callahan Advisors held 919 shares of Regeneron Pharmaceuticals worth $573K as of Q2 2026.
  • Callahan Advisors sold 5 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.4K.
  • Regeneron Pharmaceuticals made up 0.04% of Callahan Advisors's portfolio in Q2 2026, its #133 holding.
  • Callahan Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Callahan Advisors's Regeneron Pharmaceuticals position peaked at $714K in Q1 2026.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Callahan Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.